Online inquiry

IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12817MR)

This product GTTS-WQ12817MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MASP2 gene. The antibody can be applied in Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_006610.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10747
UniProt ID O00187
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12817MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8098MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ12818MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ9382MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ11462MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ1741MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ13171MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ1533MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ9114MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW